GlassScriptPhysician profile
Eugene Sangmuah
NPI 1295703338
$9,915.43
in general payments reported to CMS, 2019-2025
56 companies · $1,686 in 2025
The $1,686 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,646 · 2020: $1,396 · 2021: $1,321 · 2022: $1,274 · 2023: $1,143 · 2024: $1,449 · 2025: $1,686.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,278.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,463.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,165.70 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $856.25 | 2019-2025 | Evenity, Repatha, Otezla |
| Lilly USA, LLC | $787.29 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $667.57 | 2021-2025 | Vraylar |
| Pfizer INC. | $431.92 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $403.00 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $379.17 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $360.34 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $337.75 | 2019-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $228.21 | 2021-2025 | |
| Merz North America, INC. | $201.47 | 2020 | |
| Abbott Laboratories | $190.79 | 2022-2024 | Freestyle Libre 3, Octrode, Eterna |
| Glaxosmithkline, LLC. | $176.20 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Otsuka America Pharmaceutical, INC. | $162.87 | 2023-2025 | Rexulti, Abilify Maintena |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugene Sangmuah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.